Low aqueous solubility of active pharmaceutical ingredients (APIs) is one of the most important challenges facing drug development researchers today [1, 2]. With the development of computational chemistry and high throughput screening methods it is possible to obtain a large number of compounds with attractive therapeutic activity. However, at the same time the selection of novel active molecules with suitable biopharmaceutical properties (like solubility, intestinal permeability) becomes a great challenge and a bottleneck in drug development. Statistically, more than 40% of approved drugs and even 70–90% of those under investigations are poorly water-soluble and additional efforts are required to improve their water solubility [3–5].
- 12.Newman A (2015) Pharmaceutical amorphous solid dispersions. Wiley, Hoboken, NJGoogle Scholar
- 21.Hancock BC, Parks M (2000) What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 17(4):397–404. https://www.ncbi.nlm.nih.gov/labs/articles/10870982/ CrossRefGoogle Scholar